Hydroxyurea Should Be Continued During Acute Sickle Cell Pain Crisis
Continue hydroxyurea during an acute sickle cell pain crisis—do not stop or withhold this disease-modifying therapy. While the provided evidence does not directly address management during acute crises, the consistent guideline recommendations and clinical trial data support uninterrupted hydroxyurea therapy as the foundation of sickle cell disease management.
Rationale for Continuation
Hydroxyurea works by increasing fetal hemoglobin (HbF) levels, which takes months to achieve therapeutic effect 1. Stopping hydroxyurea during an acute crisis would eliminate its protective benefits without providing any acute benefit, as the drug's mechanism requires sustained use to maintain elevated HbF levels and reduce vaso-occlusive complications 2.
The landmark Multicenter Study of Hydroxyurea demonstrated that hydroxyurea reduces:
- Annual pain crisis rates (median 2.5 vs 4.5 per year, P<0.001) 2
- Acute chest syndrome episodes 1
- Hospitalizations and transfusion requirements 1
- Long-term mortality by up to 40% 3
Key Management Principles During Crisis
During an acute pain crisis, focus on:
- Aggressive pain management with multimodal analgesia (opioids, NSAIDs, regional techniques) 4
- Hydration - avoid dehydration through oral or IV fluids 4
- Oxygenation - maintain baseline oxygen saturation, avoid unnecessary supplemental oxygen 4
- Continue baseline hydroxyurea at the established dose
Do not hold hydroxyurea unless:
- Severe myelosuppression develops (monitor CBC) 5
- Confirmed hemolytic anemia occurs (check LDH, haptoglobin, reticulocyte count, Coombs test) 5
Monitoring Considerations
The FDA label warns about myelosuppression as the primary concern 5. During acute illness:
- Monitor complete blood counts if clinically indicated
- Leukopenia is the most common manifestation of bone marrow suppression 5
- Recovery from myelosuppression is typically rapid when therapy is interrupted 5
However, transient cytopenias during acute illness do not automatically warrant hydroxyurea discontinuation—clinical judgment based on severity is required.
Special Circumstances
Pregnancy: Hydroxyurea is teratogenic and generally contraindicated 6. However, the guideline notes it may be considered in high-risk patients during second and third trimesters 7, though this requires specialized consultation.
Perioperative setting: The perioperative guideline 4 does not recommend stopping hydroxyurea before surgery, reinforcing the principle of continuation during acute events.
Clinical Pitfall to Avoid
Do not confuse acute crisis management with chronic disease modification. Hydroxyurea prevents future crises but does not treat acute pain. The acute crisis requires standard supportive care (hydration, analgesia, oxygen if hypoxic) while maintaining disease-modifying therapy. Stopping hydroxyurea during a crisis offers no benefit and risks losing the protective effects that took months to establish 2.
The evidence consistently supports hydroxyurea as first-line disease-modifying therapy for HbSS and HbSβ⁰-thalassemia 1, 8, with benefits becoming apparent only after several months of continuous use 2. Interrupting therapy during acute events undermines long-term disease control without addressing the immediate crisis.